N-o-Carboxyphenylcarbaminsaeurephenylester | 19959-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-o-Carboxyphenylcarbaminsaeurephenylester
• 英文别名: 2-(Phenoxycarbonylamino)benzoic acid
• CAS: 19959-30-9
• 化学式: C₁₄H₁₁NO₄
• mdl: MFCD00585900
• 分子量: 257.246
• InChiKey: IXVGSIJCNIKJCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES
  申请人：SUNTORY LIMITED

  公开号：EP1142586A1

  公开（公告）日：2001-10-10

  There is provided a preventive or therapeutic agent for diseases accompanied by abnormal vascular function in which lipid deposition in the blood vessel is involved, said agent comprising a chymase inhibitor as an active ingredient. As the chymase inhibitor, a quinazoline derivative represented by the following formula is used. In the above formula, the ring A represents an aromatic ring.

  本发明提供了一种预防或治疗剂，用于治疗伴有血管功能异常的疾病，其中涉及血管中的脂质沉积，所述制剂包括作为活性成分的糜蛋白酶抑制剂。 作为糜蛋白酶抑制剂，使用了由下式表示的喹唑啉衍生物。 在上式中，环 A 代表芳香环。
• Histone deacetylases (HDACs) inhibitors
  申请人：ANNJI PHARMACEUTICAL CO., LTD.

  公开号：US11535598B2

  公开（公告）日：2022-12-27

  Histone deacetylases (HDACs) inhibitors are disclosed according to the following structural formula. The moiety A is a benzene ring, optionally substituted. The moiety B is a benzene ring attached at the 1,4 or 1,3 position, or a cyclohexane ring attached at the 1,4 position, optionally substituted. R and Z are further substituents. The HDACs inhibitors possess cytotoxicities to various cancer cell lines. They are useful for treating a tumor associated with deregulation of the activity of histone deacetylases in a subject in need thereof, in one embodiment, the HDACs inhibitors of the invention are useful for treating glioma, breast cancer, colon cancer, target cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promyiocytic leukemia, chronic myelocytic leukemia, or acute lymphocytic leukemia in a subject in need thereof.

  根据以下结构式公开了组蛋白去乙酰化酶（HDACs）抑制剂。 分子 A 是任选取代的苯环。分子 B 是连接在 1,4 或 1,3 位的苯环，或连接在 1,4 位的环己烷环，可选择被取代。R 和 Z 是进一步的取代基。HDACs 抑制剂对各种癌细胞株具有细胞毒性。在一个实施方案中，本发明的 HDACs 抑制剂可用于治疗胶质瘤、乳腺癌、结肠癌、靶细胞肺癌、肺腺癌、小细胞肺癌、胃癌、肝癌、卵巢腺癌、胰腺癌、前列腺癌、原粒细胞白血病、慢性粒细胞白血病或急性淋巴细胞白血病。
• USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION
  申请人：Daiichi Asubio Pharma Co., Ltd.

  公开号：EP1142586B1

  公开（公告）日：2007-04-25
• HISTONE DEACETYLASES (HDACS) INHIBITORS
  申请人：Annji Pharmaceutical Co., Ltd.

  公开号：EP3624804B1

  公开（公告）日：2022-02-16
• LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM
  申请人：American University of Cairo

  公开号：US20150328329A1

  公开（公告）日：2015-11-19

  Ligands that target the HCV-E2 binding site and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of E2 binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds. Identification and design of groups of compounds that bind to CD81 for use as therapeutics for treating patients infected by Hepatitis C virus and other viruses that interact with CD81. By binding to CD81, these molecules can block 1) HCV and other viral entry into cells (infection), 2) inflammatory responses caused by HCV and other viral infections, and 3) the induction of HCV associated cancers.